查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球血癌药物市场 - 2023-2030年
市场调查报告书
商品编码
1290434

全球血癌药物市场 - 2023-2030年

Global Blood Cancer Drugs Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球血癌药物市场规模在2022年达到630亿美元，预计到2030年将见证有利可图的增长，达到1135亿美元。在2023-2030年的预测期内，全球血癌药物市场预计将呈现7.8%的复合增长率。市场的主要趋势是免疫疗法的快速发展。

例如，2023年4月，下一代精准肿瘤学公司Strata Oncology, Inc.宣布推出Strata Select，这是一种针对晚期癌症患者的首次分子分析测试。

这项新的诊断测试的特点是免疫疗法反应得分，这是一种新型的多变量预测生物标志物算法，用于预测抗PD-1/PD-L1检查点抑制剂免疫疗法的益处。血癌药物包括不同的治疗干预措施，包括化疗、靶向治疗、免疫治疗和支持性护理药物，旨在专门针对并抑制血液和骨髓中的癌细胞生长。

这些药物旨在破坏异常的细胞过程，抑制癌细胞增殖，诱导细胞凋亡，并恢复正常的血细胞生成和功能。

血癌药物市场的驱动因素包括：血癌发病率的增加、癌症研究的进步、靶向治疗的发展、免疫治疗和个性化医疗。

例如，2023年5月，Amneal Pharmaceuticals, Inc.宣布推出FYLNETRA的商业化，这是一种参考Neulasta的生物仿制药，采用预装单剂量注射器。FYLNETRA用于治疗接受化疗的病人普遍出现的中性粒细胞减少症。

市场动态

血癌的发病率不断增加

血癌发病率的增加是在预测期内推动市场份额的主要因素。血癌，特别是某些类型的血癌，如白血病、淋巴瘤和多发性骨髓瘤，更常在老年人中诊断出来。随着全球人口持续老龄化，血癌的总体发病率增加。

接触某些环境因素和选择不健康的生活方式会增加患血癌的风险。环境因素包括暴露于辐射、某些化学品、杀虫剂和工业污染物。不健康的行为，如吸烟、过度饮酒和久坐不动的生活方式，也会导致血癌的发生。

治疗的高成本和副作用

由于涉及广泛的研究和开发工作，以及制造和测试过程的复杂性，血癌药物往往有一个高价格标签。这些药物的成本会给病人、医疗系统和付款人带来巨大的经济负担。高昂的治疗费用会影响市场增长，阻碍病人获得血癌药物。

血癌药物会引起各种不良反应，包括疲劳、恶心、呕吐、脱发、免疫抑制和器官毒性。这些副作用会严重影响患者的生活质量和治疗依从性。管理副作用和制定支持性护理措施是改善患者疗效和市场对血癌药物接受度的重要考虑。

COVID-19影响分析

COVID-19大流行病深刻地影响了医疗保健行业，包括血癌药物市场。血癌患者被认为是脆弱的，因为他们的免疫系统受到损害，出现COVID-19严重后果的风险更高。因此，病人的管理策略已被修改，以尽量减少与病毒的接触。

一些与血癌药物有关的研究活动可能暂时被取消优先权，或被重新定向到与COVID-19有关的项目。这种研究重点的转移可能会影响血液肿瘤药物市场的药物开发和创新速度。

俄乌冲突分析

俄乌冲突对血癌药物市场产生了重大影响。冲突可能会扰乱机构和制药公司的研究和开发合作。在药物发现、临床试验和科学交流方面的合作努力可能会受到阻碍，影响创新和开发新血癌药物的步伐。

俄罗斯和乌克兰之间的冲突可能会影响血癌药物市场的国际合作和投资。由于地缘政治风险和不确定性，公司和投资者可能会谨慎对待这些市场，有可能导致投资和合作的放缓。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按癌症类型分析
  • 按治疗类型简述
  • 按给药途径分类
  • 按终端用户分类
  • 按地区分类

第4章：动态变化

  • 影响因素
    • 驱动因素
      • 血癌的发病率不断上升
      • 靶向治疗和免疫治疗的发展
    • 限制因素
      • 治疗费用高
      • 与治疗相关的副作用
    • 机会
      • 癌症研究的进步
    • 影响分析

第五章：行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • 后COVID-19或未来的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第七章：按癌症类型

  • 白血病
  • 骨髓瘤
  • 非霍奇金淋巴瘤
  • 霍奇金淋巴瘤

第8章：按治疗类型分类

  • 化疗
  • 放射治疗
  • 免疫治疗
  • 靶向治疗
  • 其他疗法

第九章：按给药途径分类

  • 口服
  • 静脉注射
  • 其他途径

第十章：按终端用户分类

  • 医院
  • 专业诊所
  • 非住院手术中心
  • 其他

第十一章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第十二章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併和收购分析

第十三章 ：公司简介

  • Amgen Inc.
    • 公司概述
    • 产品组合和描述
    • 财务概况
    • 主要发展情况
  • AstraZeneca Plc
  • Takeda Pharmaceutical Company Ltd
  • Bayer AG
  • Celgene Corporation
  • Eli Lilly
  • Bristol-Myers Squibb Company
  • Gilead Sciences Inc.
  • Daiichi Sankyo Company Ltd
  • UCB SA

第十四章：附录

简介目录
Product Code: PH3416

Market Overview

The Global Blood Cancer Drugs Market size reached US$ 63 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 113.5 billion by 2030. The Global Blood Cancer Drugs Market is expected to exhibit a CAGR of 7.8% during the forecast period 2023-2030. The key market trend is the rapid advancements of immunotherapies.

For instance, in April 2023, Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, announced the launch of Strata Select, a first-of-its-kind molecular profiling test for patients with advanced cancer.

The new diagnostic test features the Immunotherapy Response Score, a novel multivariate predictive biomarker algorithm for anti-PD-1/PD-L1 checkpoint inhibitor immunotherapy benefit. Blood cancer drugs encompass diverse therapeutic interventions, including chemotherapy, targeted therapies, immunotherapies, and supportive care medications, designed to specifically target and inhibit the growth of cancerous cells in the blood and bone marrow.

These drugs aim to disrupt abnormal cellular processes, suppress cancer cell proliferation, induce apoptosis, and restore normal blood cell production and function.

The blood cancer drugs market is driven by factors such as the increasing prevalence of blood cancers, advancements in cancer research, development of targeted therapies, immunotherapies, and personalized medicine.

For instance, in May 2023, Amneal Pharmaceuticals, Inc. announced the commercial launch of FYLNETRA, a biosimilar referencing Neulasta in a pre-filled single-dose syringe. FYLNETRA is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy.

Market Dynamics

Increasing prevalence of blood cancers

The increasing prevalence of blood cancers is the major factor driving the market share during the forecast period. Blood cancers, particularly certain types such as leukemia, lymphoma, and multiple myeloma, are more commonly diagnosed in older individuals. As the global population continues to age, the overall incidence of blood cancers increases.

Exposure to certain environmental factors and unhealthy lifestyle choices can increase the risk of developing blood cancers. Environmental factors include exposure to radiation, certain chemicals, pesticides, and industrial pollutants. Unhealthy behaviors like smoking, excessive alcohol consumption, and a sedentary lifestyle can also contribute to the development of blood cancers.

High cost and side effects of treatment

Blood cancer drugs often come with a high price tag due to the extensive research and development efforts involved and the complexity of manufacturing and testing processes. The cost of these drugs can pose a significant financial burden on patients, healthcare systems, and payers. The high cost of treatment can impact market growth and hinder patient access to blood cancer drugs.

Blood cancer drugs can cause various adverse effects, including fatigue, nausea, vomiting, hair loss, immunosuppression, and organ toxicity. These side effects can significantly impact patients' quality of life and treatment adherence. Managing side effects and developing supportive care measures are important considerations in improving patient outcomes and market acceptance of blood cancer drugs.

COVID-19 Impact Analysis

The COVID-19 pandemic has profoundly impacted the healthcare industry, including the blood cancer drugs market. Blood cancer patients are considered vulnerable due to their compromised immune systems and higher risk of severe COVID-19 outcomes. As a result, patient management strategies have been modified to minimize exposure to the virus.

Some research activities related to blood cancer drugs may have been temporarily deprioritized or redirected towards COVID-19-related projects. This shift in research focus may impact the pace of drug development and innovation in the blood cancer drugs market

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has significantly impacted the blood cancer drugs market. The conflict may disrupt research and development collaboration in institutions and pharmaceutical companies. Collaborative efforts in drug discovery, clinical trials, and scientific exchange may be hampered, impacting the pace of innovation and development of new blood cancer drugs.

The conflict between Russia and Ukraine may impact international collaborations and investments in the blood cancer drugs market. Companies and investors may approach these markets with caution due to geopolitical risks and uncertainties, potentially leading to a slowdown in investments and collaborations.

Segment Analysis

The Global Blood Cancer Drugs Market is segmented based on cancer type, therapy type, route of administration, End User, and region.

Based on cancer type, the leukemia segment is expected to dominate the market share

The leukemia market will hold 35.8% of the global blood cancer drugs market share in 2022. Leukemia has been the subject of extensive research and development efforts in the field of blood cancer drugs. Significant advancements have been made in understanding the molecular basis of different leukemia subtypes, leading to the development of targeted therapies and immunotherapies.

For instance, in May 2023, Shorla Oncology, a U.S.-Ireland pharmaceutical company, and EVERSANA, a leading provider of commercialization services to the life science industry, announced the commercial launch of the company's oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in adult and pediatric patients aged one year and older.

Geographical Analysis

North America holds the largest market share due to the presence of key players and advanced healthcare infrastructure

North America holds the 41.3% market share for the blood cancer drugs market in 2022 due to the presence of key players and advanced healthcare infrastructure in the region. North America boasts advanced healthcare infrastructure, including well-established hospitals, research institutions, and oncology centers.

The region has a robust healthcare system that facilitates access to diagnosis, treatment, and follow-up care for blood cancer patients. The availability of state-of-the-art medical facilities, advanced diagnostic technologies, and specialized healthcare professionals supports the demand for blood cancer drugs and drives market growth.

Competitive Landscape

The major global players in the market include: Amgen Inc., AstraZeneca Plc, Takeda Pharmaceutical Company Ltd, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead Sciences Inc., Daiichi Sankyo Company Ltd, and UCB SA.

Why Purchase the Report?

  • To visualize the Global Blood Cancer Drugs Market segmentation based on cancer type, therapy type, route of administration, End User, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of blood cancer drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Blood Cancer Drugs Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Cancer Type
  • 3.2. Snippet by Therapy Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of blood cancers
      • 4.1.1.2. Development of targeted therapies and immunotherapies
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of treatment
      • 4.1.2.2. Side effects associated with treatment
    • 4.1.3. Opportunity
      • 4.1.3.1. Advancements in cancer research
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Cancer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 7.1.2. Market Attractiveness Index, By Cancer Type
  • 7.2. Leukemia*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Myeloma
  • 7.4. Non-Hodgkin Lymphoma
  • 7.5. Hodgkin Lymphoma

8. By Therapy Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 8.1.2. Market Attractiveness Index, By Therapy Type
  • 8.2. Chemotherapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Radiation Therapy
  • 8.4. Immunotherapy
  • 8.5. Targeted Therapy
  • 8.6. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Parenteral
  • 9.4. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Amgen Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. AstraZeneca Plc
  • 13.3. Takeda Pharmaceutical Company Ltd
  • 13.4. Bayer AG
  • 13.5. Celgene Corporation
  • 13.6. Eli Lilly
  • 13.7. Bristol-Myers Squibb Company
  • 13.8. Gilead Sciences Inc.
  • 13.9. Daiichi Sankyo Company Ltd
  • 13.10. UCB SA

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us